Targeting renal cell carcinoma with a HIF-2 antagonist
2016 · Nature · 704 citations
https://doi.org/10.1038/nature19796
E
Eli M. Wallace
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
37
Papers
3.5K
Citations
21
h-index
24
i10-index
Eli M. Wallace is an academic researcher from BridgeBio (United States). The author has contributed to research in topics: Cancer, Hypoxia, and Metabolism & PI3K/AKT/mTOR signaling in cancer & Asymmetric Synthesis and Catalysis. The author has an h-index of 21, co-authored 32 publications.
Papers by this author
worksOn-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
2016 · Nature · 448 citations
https://doi.org/10.1038/nature19795
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
2016 · Cancer Research · 316 citations
https://doi.org/10.1158/0008-5472.can-16-0473
3-[(1<i>S</i>,2<i>S</i>,3<i>R</i>)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma
2019 · Journal of Medicinal Chemistry · 202 citations
https://doi.org/10.1021/acs.jmedchem.9b00719
Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension
2019 · European Respiratory Journal · 115 citations
https://doi.org/10.1183/13993003.00378-2019
Targeting HIF2α-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension
2020 · European Respiratory Journal · 34 citations
https://doi.org/10.1183/13993003.02061-2019
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat